scholarly journals Clinical Evaluation of Pinggan Yiqi Yangshen Recipe Combined with Labetalol Hydrochloride and Magnesium Sulfate in the Treatment of PIH

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Ping Li ◽  
Jie Zhao ◽  
Peipei Gao ◽  
Hongcui Qu
Keyword(s):  
Blood Pressure ◽  
Renal Function ◽  
Magnesium Sulfate ◽  
Pregnancy Outcomes ◽  
Adverse Reactions ◽  
Fetal Distress ◽  
Effective Rate ◽  
Control Group ◽  
Labetalol Hydrochloride ◽  
Experimental Group

Background. To observe the clinical effect of Pinggan Yiqi Yangshen recipe combined with labetalol hydrochloride and magnesium sulfate in the treatment of pregnancy-induced hypertension (PIH). Methods. A total of 126 patients with PIH diagnosed in our hospital from January 2016 to May 2018 were randomly divided into the control group and the experimental group, with 63 cases in each group. The control group was treated with labetalol combined with magnesium sulfate. On the basis of the control group, the experimental group was treated with Pinggan Yiqi Yangshen recipe. Clinical efficacy, blood pressure, renal function, and biochemical indexes were compared between the two groups. Moreover, pregnancy outcomes and adverse reactions were compared between the two groups. Results. After treatment, the total effective rate in the experimental group was higher than in the control group. Blood pressure and mean arterial pressure in the experimental group were more significantly downregulated than the control group. Renal function indexes and biochemical indexes in the experimental group were more significant than those in the control group. The incidence of cesarean section, preterm birth, and abnormal fetal heart rate in the experimental group was significantly lower than that in the control group. There was no difference in the incidence of fetal distress, postpartum hemorrhage, neonatal asphyxia, and adverse reactions between the two groups. Conclusion. Pinggan Yiqi Yangshen recipe combined with labetalol hydrochloride and magnesium sulfate can effectively reduce the blood pressure of patients with PIH, help patients to return to normal levels of biochemical indexes and renal function indexes, and improve pregnancy outcomes with high safety, which is worthy of further promotion and application in clinical practice.

scholarly journals Therapeutic effect of nifedipine combined with enalapril on elderly patients with coronary heart disease complicated with hypertension

2018 ◽  
Vol 2 (6) ◽  
Author(s):  
Xiaoye Wang
Keyword(s):  
Blood Pressure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Elderly Patients ◽  
Adverse Reactions ◽  
Effective Rate ◽  
Control Group ◽  
Significant Difference ◽  
Pre Treatment ◽  
Experimental Group

【Abstract】Objective: Toanalyze the efficacy of combined drug therapy for elderly patients with coronary heart disease and hypertension.METHODS:Sixty-six elderly patients with coronary heart disease and hypertension were enrolled from December 2017 to November 2018. They were randomly divided into two groups, 33 patients in each group. Patients in the experimental group received nifedipine. In combination with enalapril, patients enrolled in the control group received nifedipine monotherapy.RESULTS:Compared with the control group, the total effective rate, Serum Nitric Oxide (Serum NO) after treatment, CRP after treatment, HCY after treatment, and blood pressure after treatment were significantly improved (P<0.05). Serum NO and treatment before treatment in the 2 groups. There was no significant difference in pre-CRP, pre-treatment HCY, pre-treatment blood pressure, and adverse reactions during treatment (P>0.05).Conclusion: Theelderly patients with coronary heart disease and hypertension are treated with nifedipine and enalapril.

scholarly journals Microvascular decompression for the treatment of neurogenic hypertension with trigeminal neuralgia

BMC Neurology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Wenchao Lu ◽  
Hui Wang ◽  
Zhongnan Yan ◽  
Yuangang Wang ◽  
Hongmin Che
Keyword(s):  
Blood Pressure ◽  
Trigeminal Neuralgia ◽  
Trigeminal Nerve ◽  
Microvascular Decompression ◽  
Effective Rate ◽  
Ventrolateral Medulla ◽  
Control Group ◽  
Hypertensive Patients ◽  
Significant Difference ◽  
Experimental Group

Abstract Background To evaluate the efficacy of microvascular decompression (MVD) in reducing hypertension (HTN) in hypertensive patients with trigeminal neuralgia (TN). Methods The clinical data of 58 cases of neurogenic HTN with TN treated in our hospital were retrospectively reviewed. Preoperative MR revealed abnormal blood pressure in the left rostral ventrolateral medulla (RVLM) and the posterior cranial nerve root entry zone (REZ). The patients were divided into control group: only trigeminal nerve was treated with MVD; experimental group: trigeminal nerve, RVLM and REZ were treated with MVD at the same time. The patients were followed up for 6 months to 1 year to observe the changes of blood pressure. Results There was no significant difference in gender, age, course of TN, course of HTN, grade of HTN and preoperative blood pressure between the two groups. After operation, the effective rate of HTN improvement with MVD was 32.1% in the control group. There was no significant difference in the preoperative and post operative blood pressure. (P△SBP = 0.131; P△BDP = 0.078). In the experimental group, the effective rate was 83.3%. The postoperative blood pressure was significantly lower than preoperative values. (P△SBP < 0.001; P△DBP < 0.001). Conclusions MVD is an effective treatment for neurogenic HTN. However, the criteria for selecting hypertensive patients who need MVD to control their HTN still needs to be further determined. Possible indications may include: left trigeminal neuralgia, neurogenic HTN; abnormal blood pressure compression in the left RVLM and REZ areas on MR; and blood pressure in these patients can not be effectively controlled by drugs.

scholarly journals Effect of Entecavir Combined with Adefovir Dipivoxil on Clinical Efficacy and TNF-α and IL-6 Levels in Patients with Hepatitis B Cirrhosis

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Yonghuan Yu ◽  
Xinfeng Cui ◽  
Jingjing Zhao ◽  
Ting Jia ◽  
Baofeng Ren ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hepatitis B ◽  
Liver Function ◽  
Adefovir Dipivoxil ◽  
Adverse Reactions ◽  
Statistical Significance ◽  
Effective Rate ◽  
Control Group ◽  
Tnf Α ◽  
Experimental Group

Objective. The purpose of the study was to investigate the effect of entecavir combined with adefovir dipivoxil on clinical efficacy and TNF-α and IL-6 levels in patients with hepatitis B cirrhosis. Methods. A total of 100 patients with hepatitis B cirrhosis admitted to our hospital between January 2018 and June 2019 were randomly selected and divided into the control group (n = 50) and experimental group (n = 50) according to the order of admission. Among them, the control group patients were treated with entecavir, while the patients in the experimental group received entecavir combined with adefovir dipivoxil. After that, the effective rate of treatment, the incidence of adverse reactions, liver function indexes, liver fibrosis condition, and TNF-α and IL-6 expression levels were all compared between the two groups. Results. The effective rate of treatment in the experimental group was significantly higher than that in the control group, with statistical significance ( p < 0.001 ); the incidence of adverse reactions of the patients in the experimental group was significantly lower than that in the control group, with statistical significance ( p < 0.001 ); the liver function indexes in the experimental group were significantly better than those in the control group, with statistical significance ( p < 0.001 ); the number of patients with liver fibrosis in the experimental group was significantly less than that in the control group, with statistical significance ( p < 0.001 ); the TNF-α and IL-6 expression levels in the experimental group were significantly lower than those in the control group, with statistical significance ( p < 0.001 ). Conclusion. Entecavir combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis can effectively improve the therapeutic effect and reduce the serum inflammatory factor levels, with high safety, which is worthy of application and popularization.

scholarly journals Efficacy and Safety of Omeprazole and Amoxicillin in the Treatment of Gastric Ulcer

2021 ◽  
Vol 5 (3) ◽  
Author(s):  
Jie Liu ◽  
Minghui Xiao ◽  
Jianping Hui
Keyword(s):  
Gastric Ulcer ◽  
Recurrence Rate ◽  
Breath Test ◽  
Adverse Reactions ◽  
Effective Rate ◽  
Control Group ◽  
Research Subjects ◽  
Before And After ◽  
Positive Rate ◽  
Experimental Group

Objective: To study the effect of omeprazole and amoxicillin in the treatment of patients with gastric ulcer. Methods: 88 patients with gastric ulcer in our hospital from March 2018 to March 2020 were selected as research subjects and divided into experimental group (44 cases were treated with omeprazole + amoxicillin) and control group (44 cases were treated with omeprazole). The therapeutic effect, positive rate of breath test before and after treatment, recurrence rate within half a year and adverse reactions were compared between the two groups. Results: The total effective rate of the experimental group (97.73%, 43 / 44) was higher than that of the control group (84.09%, 37 / 44), P < 0.05; After treatment, the positive rate of breath test in the experimental group (22.73%, 10 / 44) was lower than that in the control group (47.73%, 21 / 44), P < 0.05; The recurrence rate in the experimental group was 4.55% (2 / 44), which was significantly higher than that in the control group (20.45%, 9 / 44), P < 0.05; The incidence of adverse reactions in the experimental group (9.09%, 4 / 44) was significantly lower than that in the control group (15.91%, 7 / 44), P < 0.05. Conclusion: In the process of clinical treatment of gastric ulcer, omeprazole combined with amoxicillin has significant effect, not only the recurrence rate is low, but also the incidence of adverse events should be less, and the treatment is safer. 

Clinical Effect Analysis of Jianpi Bushen Yiqi Decoction on Patients with Chronic Nephritis

2021 ◽  
Vol 7 (5) ◽  
pp. 1383-1388
Author(s):  
Shujuan Mu ◽  
Jun Chen ◽  
Jing Chen ◽  
Xue Li ◽  
Yingxu Chen ◽  
...  
Keyword(s):  
Renal Function ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Effective Rate ◽  
Urinary Protein ◽  
Control Group ◽  
Observation Group ◽  
Chronic Nephritis ◽  
Tcm Syndrome ◽  
Better Than

Select the actual clinical effect of Jianpi Bushen Yiqi Decoction on patients with chronic nephritis. Methods: A total of 60 patients with chronic nephritis who were admitted to our hospital from January 2018 to January 2019 were selected. They were divided into 2 groups according to the admission order, 30 cases each. The control group was treated with conventional western medicine, and the observation group was treated with Jianpi Bushen Yiqi Decoction on the basis of the control group. The renal function indexes and urinary protein index, clinical efficacy, TCM syndrome scores, and adverse reactions were compared between the two groups. Result: There was no difference in renal function and urinary protein indexes between the two groups before treatment (P> 0.05). After treatment, the indicators in the observation group were better than those in the control group (P <0.05). The total effective rate of treatment in the observation group was higher than that in the control group (P <0.05). There was no difference in TCM syndrome scores between the first two groups (P> 0.05). After treatment, the indicators in the observation group were better than those in the control group (P <0.05). The overall incidence of adverse reactions in the observation group was lower than that in the control group (P <0.05). Conclusion: Jianpi Bushen Yiqi Decoction has a significant effect on chronic nephritis, which can effectively improve the renal function and urinary protein index of patients, with few adverse reactions and great application value.

scholarly journals Analysis of the Effect of Pantoprazole and Omeprazole on Pain Relief in Patients with Gastric Ulcer

2021 ◽  
Vol 5 (3) ◽  
Author(s):  
Minghui Xiao ◽  
Jie Liu ◽  
Jianping Hui
Keyword(s):  
Helicobacter Pylori ◽  
Gastric Ulcer ◽  
Pain Relief ◽  
Recurrence Rate ◽  
Conversion Rate ◽  
Adverse Reactions ◽  
Effective Rate ◽  
Control Group ◽  
Experimental Group ◽  
Negative Conversion

Objective: To analyze the effect of pantoprazole and omeprazole in the treatment of patients with gastric ulcer. Methods: The treatment effect, recurrence rate, helicobacter pylori negative conversion rate, adverse reaction status and pain relief time of the two groups were compared. Results: The total effective rate of the experimental group (97.78%, 44 / 45) was higher than that of the control group (84.44%, 38 / 45), P < 0.05;The recurrence rate (4.44%, 2 / 45) and Helicobacter pylori negative conversion rate (95.56%, 43 / 45) of the experimental group were significantly higher than those of the control group (P < 0.05); The incidence of adverse reactions in the experimental group (11.11%, 5 / 45) was lower than that in the control group (15.56%, 7 / 45) (P > 0.05);The pain relief time of the experimental group was (2.24 ± 1.16) d, which was shorter than that of the control group (P < 0.05). Conclusion: In the process of clinical treatment of gastric ulcer, pantoprazole has significant curative effect and low recurrence rate, which can eradicate Helicobacter pylori as soon as possible, shorten the pain time and make the treatment safer.

scholarly journals Efficacy of Restricting Dietary Protein Intake Combined with Buyang Huanwu Decoction in Treating Diabetic Nephropathy and Its Effect on Patients’ Inflammatory Factor Levels

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Dan Chen ◽  
Dan Huang ◽  
Taotao Hu ◽  
Fang Chen
Keyword(s):  
Renal Function ◽  
Dietary Protein ◽  
Protein Intake ◽  
Effective Rate ◽  
Control Group ◽  
Inflammatory Factor ◽  
Dietary Protein Intake ◽  
Buyang Huanwu Decoction ◽  
Experimental Group ◽  
Better Than

Objective. To study the efficacy of restricting dietary protein intake combined with Buyang Huanwu decoction in treating diabetic nephropathy (DN) and its effect on patients’ inflammatory factor levels. Methods. The medical data of 150 DN patients treated in Wuhan No.1 Hospital (June 2018—May 2021) were retrospectively analyzed. All patients received regular therapy, those who received the intervention of restricting dietary protein intake were included in the control group (n = 75), and on this basis, those treated with Buyang Huanwu decoction were included in the experimental group (n = 75), so as to scientifically evaluate their efficacy and inflammatory factor levels after treatment. Results. The patients’ general information was not statistically different between the two groups ( P > 0.05 ); after treatment, the experimental group gained remarkably higher marked effective rate and total effective rate of treatment than the control group ( P < 0.05 ); the inflammatory factor levels of all patients were obviously better than before ( P < 0.05 ), and the levels of TNF-α, IL-2, IL-8, IL-4, and IL-10 were obviously lower in the experimental group than in the control group ( P < 0.05 ); the levels of fasting blood glucose, 2 h postprandial blood glucose, and glycosylated hemoglobin of all patients were remarkably lower than before ( P < 0.05 ), but with no significant between-group difference ( P > 0.05 ); the renal function indexes of all patients were better than before, and between the two groups, the levels of 24 h microalbuminuria, 24 h urine protein excretion, and serum creatinine were obviously lower and the glomerular filtration rate was significantly higher in the experimental group ( P all <0.05), and the patients’ traditional Chinese medicine (TCM) symptom scores were remarkably lower in the experimental group ( P < 0.05 ). Conclusion. Jointly applying Buyang Huanwu decoction on the basis of restricting dietary protein intake can effectively promote the clinical efficacy of DN, which is conducive to adjusting the inflammatory factor levels, promoting the patients’ renal function, and alleviating the clinical symptoms.

scholarly journals Clinical application effect evaluation of Kanglaite combined with DCF chemotherapy program in patients with gastric cancer

2017 ◽  
Vol 1 (3) ◽  
Author(s):  
Haibin Ding
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Clinical Application ◽  
Adverse Reactions ◽  
Life Quality ◽  
Effective Rate ◽  
Control Group ◽  
Therapeutic Effects ◽  
Experimental Group

Objective: To evaluate the clinical application effect of Kanglaite combined with DCF chemotherapy program in the patients with gastric cancer. Methods: 86 cases who were all the gastric cancer patients admitted to our hospital from February 2014 to June 2016 were selected, according to randomly divided into two groups, control group and experimental group. The control group was treated with DCF treatment, and the experimental group were treated with Kanglaite combined DCF chemotherapy program, and the therapeutic effects, the quality of life of patients and incidence rate of adverse reactions in two groups were observed and compared. Result: Compared with the control group, the total effective rate and the quality of life score of the experimental group were significantly higher, and the incidence of adverse reactions was less (P < 0.05). Conclusion: In clinic, Kanglaitecombined with DCF chemotherapy program on patients with gastric cancer, can improve the treatment effect and life quality of patients, with less adverse reaction and high application value.

Preparation of Targeted Drug-Loaded Nanobubbles and Its Effect in Improvement of Renal Function in Patients with Hyperuricemia

2021 ◽  
Vol 13 (3) ◽  
pp. 509-515
Author(s):  
Han Xia ◽  
Yujing Zhang ◽  
Gengxin Guo ◽  
Aixiang Liu ◽  
Jing Liu
Keyword(s):  
Renal Function ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Effective Rate ◽  
Control Group ◽  
Before And After ◽  
Targeted Drug ◽  
The Difference ◽  
Experimental Group

The effects of targeted drug-loaded nanobubble (DLNB) on the treatment of patients with hyperuricemia (HUA) and the improvement of renal function were explored by constructing targeted DLNB. G250 targeted allopurinol-loaded NB (ANBs) was prepared by filming-rehydration method and its physicochemical properties were investigated. A total of 80 patients with HUA admitted to the hospital from July 2017 to July 2019 were selected and divided into control group and experimental group, with 40 patients in each group, treated for 4 weeks. Blood UA (UA), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), blood creatinine (Cr) and other related indicators were compared before and after treatment. Targeted ANBs was successfully constructed and its targeting in vitro was guaranteed. The effective rate of control group was 65.00%, and that of experimental group was 77.50%, with evident difference (P < 0.05). In contrast to control group, UA, TC, TG, HDL, and LDL were notably decreased in the experimental group after treatment, and the difference was evident (P < 0.05). ALT, AST, BU, and Cr also showed notable improvement (P < 0.05). Targeted ANBs had good therapeutic effect on patients with HUA, and it also played a certain role in improving liver function and kidney function in HUA patients.

scholarly journals Effect of Cinepazide Maleate Combined with Promethazine Hydrochloride in the Treatment of Emergency Vertigo

2021 ◽  
Vol 5 (3) ◽  
Author(s):  
Jun Yi ◽  
Yincai Zhou ◽  
Xinghao Cheng
Keyword(s):  
Quality Of Life ◽  
Adverse Reactions ◽  
Clinical Symptoms ◽  
Symptom Relief ◽  
Effective Rate ◽  
Control Group ◽  
Combined Application ◽  
Promethazine Hydrochloride ◽  
Experimental Group

Objective: To explore the effect of cinepazide maleate combined with promethazine hydrochloride in the treatment of emergency vertigo. Methods: 48 cases of emergency vertigo patients in our hospital from November 2017 to November 2019 were divided into experimental group (24 cases, treated with cinepazide maleate combined with promethazine hydrochloride) and control group (24 cases, treated with cinepazide maleate). The clinical efficacy, symptom relief time, adverse reactions and quality of life were compared. Results: The total effective rate of the experimental group (95.83%, 23 / 24) was higher than that of the control group (75.00%), The remission time of nausea and vomiting (1.75 ± 0.22) d, vertigo (3.54 ± 0.63) d, deafness and tinnitus (3.47 ± 0.58) d, night sweats (3.05 ± 0.33) d in the experimental group were shorter than those in the control group, P < 0.05; the incidence of adverse reactions in the experimental group (8.33%, 2 / 24) was lower than that in the control group (33.33%, The scores of social function, material life attitude, physical health and psychological function in the experimental group were 59.14 ± 7.23, 54.05 ± 8.04, 53.58 ± 8.86 and 60.11 ± 8.44 respectively, P < 0.05. Conclusion: In the process of clinical treatment of emergency vertigo patients, the combined application of cinepazide maleate and promethazine hydrochloride has definite curative effect, can relieve clinical symptoms in a short time, has less adverse reactions, and improves the quality of life of patients to a certain extent, which is worthy of promotion.

Sign in / Sign up

Export Citation Format

Share Document